Orina verde / Green urine

Junio 13, 2017. No. 2718

Orina verde debida a infusión de propofol Green urine due to propofol infusion. Urraca-Espeje C1, Portero-Portaz JJ1, Córdoba-Soriano JG2. Med Intensiva. 2016 Nov;40(8):524. doi: 10.1016/j.medin.2015.08.009. Epub 2015 Dec 1. PDF Orina verde. ¿Un motivo de preocupación? Green urine: A cause for concern? Prakash S1, Saini S1, Mullick P1, Pawar M1. J Anaesthesiol Clin Pharmacol. 2017 Jan-Mar;33(1):128-130. doi: 10.4103/0970-9185.202190. PDF Orina verde Green urine. Koratala A1, Leghrouz M1. Clin Case Rep. 2017 Mar 8;5(4):549-550. doi: 10.1002/ccr3.891. eCollection 2017 Apr. Abstract Methylene blue is used to assess the integrity of the bowel and may cause self-limiting bluish or greenish hue to the urine. Green urine is also caused by medications such as propofol and infections such as pseudomonas. Knowledge of the benign nature of this condition prevents unnecessary consultations and anxiety. KEYWORDS: Green urine; methylene blue; propofol; pseudomonas PDF  Orina verde y síntomas extrapiramidales Green urine and extrapyramidal symptoms. Jayasree K1, Sangeetha B2, Chaitanya V2, Subramanyam BV1, Ram R2, Kumar VS1. Saudi J Kidney Dis Transpl. 2016 Sep-Oct;27(5):1055-1056. doi: 10.4103/1319-2442.190888. PDF Coloración verde de la orina relacionada con infusión de propofol M. Batllori Gastóna,1, A. Rivero Marcoteguia,2, M. Castañeda Pascuala,1, E. Murillo Jasob, Rev. Esp. Anestesiol. Reanim. 2009; 56: 334 PDF Orina verde secundaria a propofol Sara Fernández, Pedro Castro, Santiago Nogué, Jose María Nicolás Med Clin 2013;141:463   PDF Orina verde debida a propofol. Informe de caso y revisión de la literatura Green Urine Due to Propofol: A Case Report with Review of Literature. Rawal G1, Yadav S2. J Clin Diagn Res. 2015 Nov;9(11):OD03-4. doi: 10.7860/JCDR/2015/15681.6706. Epub 2015 Nov 1.Abstract The change in the colour of urine is a known occurrence in an intensive care setting and is always a cause of concern to the clinicians who have to differentiate between benign and pathological causes. Herein, we present a case of 62-year-old postoperative lady, noticed to be passing green coloured urine believed to be due to intravenous Propofol administration for induction of general anaesthesia. The green colour of urine due to Propofol occurs when clearance of Propofol exceeds hepatic elimination, and extrahepatic elimination of Propofol occurs. This discolouration of urine is a rare (less than 1% cases) but a benign side effect of Propofol, which is non-nephrotoxic and gets reversed after discontinuation of the drug. KEYWORDS: Anaesthesia; Drug side effect; Urine discoloration PDF

Anestesiología y Medicina del Dolor 52 664 6848905 vwhizar@anestesia-dolor.org anestesia-dolor.org

Enfermedad de Hirschsprung

Conferencia por el Dr. Luis de la Torre Mondragon,Enfermedad de Hirschsprung, actualidades en su manejo. Por problemas técnicos fuera del alcance de nuestras manos el Dr No tenia buen ancho de banda, pero había grabado su conferencia ante la sospecha de esta eventualidad. Describe la enfermedad desde el nacimiento del bebe y la sospecha clínica. Es una enfermedad rectal y es la mas frecuente, no hacemos el diagnostico tempranamente y lo mas triste es que estos pacientes fallecen por complicaciones, describe su diagnostico debe ser anatomopatológico, su manejo clínico y debe ser evaluado por un cirujano pediatra, operado tempranamente

Ciberpeds: http://ciberpeds. kxs.mx/

conapeme: http://bit.ly/ 2rgIa0q

Registro a conferencias offfLine: http://bit.ly/ 2rZbWrQ

es importante escribir el titulo de la conferencia y en ocaciones no hay preguntas por el profesor por problemas técnicos por lo que no tienen que contesaralas.

Dr. Enrique Mendoza López
Webmaster: CONAPEME
Coordinador Nacional: Seminario Ciberpeds-Conapeme
Av La Clinica 2520-310 col Sertoma
Monterrey N.L. CP 64718
Tel (81) 83482940, (81)81146053
 Cel 0448183094806

Embarazo y hepatitis viral / Viral hepatitis and pregnancy

Junio 15, 2017. No. 2720

Actualización de hepatitis viral y embarazo Update on viral hepatitis in pregnancy. Shao Z1, Al Tibi M2, Wakim-Fleming J3. Cleve Clin J Med. 2017 Mar;84(3):202-206. doi: 10.3949/ccjm.84a.15139. Abstract Pregnant women with acute viral hepatitis are at higher risk of morbidity and death than pregnant women with chronic viral hepatitis. The risk of death is highest with acute viral hepatitis E, and the rate of transmission to the baby may be highest with hepatitis B virus (HBV) infection. Managing viral hepatitis in pregnancy requires assessing the risk of transmission to the baby, determining the gestational age at the time of infection and the mother's risk of decompensation, and understanding the side effects of antiviral drugs. PDF Hepatitis B en la detección, tratamiento y prevención de la transmisión vertical en el embarazo. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Society for Maternal-Fetal Medicine (SMFM), Dionne-Odom J1, Tita AT1, Silverman NS1. Am J Obstet Gynecol. 2016 Jan;214(1):6-14. doi: 10.1016/j.ajog.2015.09.100. Epub 2015 Oct 8. Abstract Between 800,000-1.4 million people in the United States and more than 240 million people worldwide are infected with hepatitis B virus (HBV). Specific to pregnancy, an estimated prevalence of 0.7-0.9% for chronic hepatitis B infection among pregnant women in the United States has been reported, with >25,000 infants at risk for chronic infection born annually to these women. Vertical transmission of HBV from infected mothers to their fetuses or newborns, either in utero or peripartum, remains a major source of perpetuating the reservoir of chronically infected individuals globally. Universal screening for hepatitis B infection during pregnancy has been recommended for many years. Identification of pregnant women with chronic HBV infection through universal screening has had a major impact in decreasing the risk of neonatal infection. The purpose of this document is to aid clinicians in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B infection in the absence of coinfection with HIV. We recommend the following: (1) perform routine screening during pregnancy for HBV infection with maternal HBsAg testing (grade 1A); (2) administer hepatitis B vaccine and HBV immunoglobulin within 12 hours of birth to all newborns of HBsAg-positive mothers or those with unknown or undocumented HBsAg status, regardless of whether maternal antiviral therapy has been given during the pregnancy (grade 1A); (3) In pregnant women with HBV infection, we suggest HBV viral load testing in the third trimester (grade 2B); (4) in pregnant women with HBV infection and viral load >6-8 log 10 copies/mL, HBV-targeted maternal antiviral therapy should be considered for the purpose of decreasing the risk of intrauterine fetal infection (grade 2B); (5) in pregnant women with HBV infection who are candidates for maternal antiviral therapy, we suggest tenofovir as a first-line agent (grade 2B); (6) we recommend that women with HBV infection be encouraged to breast-feed as long as the infant receives immunoprophylaxis at birth (HBV vaccination and hepatitis B immunoglobulin) (grade 1C); (7) for HBV infected women who have an indication for genetic testing, invasive testing (eg amniocentesis or chorionic villus sampling) may be offered-counseling should include the fact that the risk for maternal-fetal transmission may increase with HBV viral load >7 log 10 IU/mL (grade 2C); and (8) we suggest cesarean delivery not be performed for the sole indication for reduction of vertical HBV transmission (grade 2C). KEYWORDS: antiviral therapy; breast-feeding; chronic hepatitis; hepatitis B; immunoprophylaxis; vertical transmission; viral load PDF Hepatitis viral durante el embarazo Valdés R E1, Sepúlveda M A, Candia P P, Lattes A K. Rev Chilena Infectol. 2010 Dec;27(6):505-12. doi: /S0716-10182010000700003. Epub 2011 Jan 7. Abstract Acute hepatitis has a very low incidence disease during pregnancy. However, it may be an important cause of jaundice during gestation which in cases of viral etiology can have a very high morbidity and mortality risk to the mother and the fetus. The purpose of this review is to update the available knowledge regarding viral hepatitis during pregnancy including description of the main etiologies, transmission route, maternal-fetal risk and possible management. PDF

Anestesiología y Medicina del Dolor 52 664 6848905 vwhizar@anestesia-dolor.org anestesia-dolor.org